Novain (Oxybuprocaine Hydrochloride)

Novain (oxybuprocaine hydrochloride) is used as a topical ophthalmic anesthetic to temporarily block sensory nerves during eye procedures.

• Diagnostic ocular procedures: provides rapid surface anesthesia for slit‑lamp examinations and intraocular pressure measurements.
• Minor ocular surgery: enables painless corneal suturing, laser photocoagulation, or foreign‑body extraction.
• Corneal abrasion or foreign body removal: relieves acute pain and discomfort during debridement.

• Oxybuprocaine hydrochloride acts by reversibly binding to voltage‑gated sodium channels on peripheral nerve membranes in the corneal and conjunctival epithelium. This blockade prevents the influx of sodium ions required for depolarisation, thereby inhibiting initiation and propagation of nerve impulses. The effect is localized to the ocular surface, producing rapid loss of sensation without systemic absorption. The reversible nature of the binding allows normal sensation to return within minutes after the drug is cleared from the ocular surface.

Oxybuprocaine hydrochloride may cause transient ocular reactions, and rare severe events have been reported.

Common Side Effects

• Stinging or burning sensation upon instillation.
• Transient blurred vision.
• Conjunctival redness.
• Mild tearing.

Serious or Rare Side Effects

• Corneal epithelial toxicity with prolonged exposure.
• Severe allergic reaction, including anaphylaxis.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Persistent ocular inflammation that may threaten vision.

When using Novain, clinicians should observe several safety measures to minimise ocular irritation and systemic risk.

• Allergy assessment: avoid in patients with known hypersensitivity to ester‑type ophthalmic anesthetics.
• Contact lens wearers: remove lenses before instillation to prevent drug accumulation.
• Compromised corneal epithelium: use with caution in eyes with epithelial defects or infections.
• Pregnancy and lactation: safety not established; prescribe only if benefit outweighs potential risk.
• Store at room temperature: keep in original container, protect from light and moisture.

Oxybuprocaine hydrochloride can interact with other ophthalmic agents, affecting ocular tolerance or systemic sodium channel activity.

Major Interactions (Avoid)

• Concurrent use of other topical ocular anesthetics: may cause additive corneal toxicity.
• Systemic administration of local anesthetics: increased risk of cumulative sodium channel blockade.
• Preservative‑rich eye drops combined with oxybuprocaine: heightened irritation and epithelial damage.

Moderate Interactions (Monitor Closely)

• Beta‑blocker eye drops: may increase ocular surface irritation.
• Anticholinergic ophthalmic solutions: possible alteration of pupil response.
• Preservative‑containing contact lens solutions: monitor for increased corneal sensitivity.